ArticleBMC nephrology2025
Renal drug dosing practices and clinical outcomes in patients with kidney disease admitted at two referral hospitals in Northwest Ethiopia.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKidney disease; including acute kidney injury (AKI) and chronic kidney disease (CKD) is a significant global health burden, contributing to cardiovascular and cerebrovascular morbidity and mortality. Patients with any degree of renal disease are at risk of drug metabolism and excretory function loss. Toxicity from lack of proper drug or metabolite excretion and ineffective dosing from renal adjustment likely affects the clinical outcome of critical patients among other factors. In Ethiopia, predictors of poor outcomes related to dose adjustments remain understudied, causing uncertainty in clinical dosing practices. This study aimed to assess renal drug dose adjustment practice and patient outcomes in hospitalized patients with kidney diseases.
methodsAn institution-based, Cross-sectional study was conducted from December, 01/2023- February, 29/2024. A total of 403 patients were selected using a systematic random sampling technique. A pre-tested semi-structured questionnaire was used to collect data which was entered to Epi data version 3.1 and exported to SPSS for analysis. Descriptive statistics were used to summarize socio-demographic and clinical data, as well as the proportions of patients with poor treatment outcomes and the proportions that received different levels of renal drug dosage adjustment services. Bivariable and multivariable logistic regression analyses were employed to estimate the crude and adjusted odds ratio with a confidence interval of 95% and a P value of less than 0.05 considered statistically significant of predictors with patients treatment outcome.
resultsAmong the 384 patients with renal disease, more than one-third (36.5%), 95%CI (31.8%-41.3%) had poor treatment outcomes. The practice of renal drug dose adjustment was poor; revealing only 23.2% compliance with dosing guidelines. Partial renal drug dose adjustment (AOR= 2.76, 95% CI:1.14-6.71), no renal drug dose adjustments (AOR= 10.15, 95% CI: 3.88-26.57), mechanical ventilator use (AOR=2.90, 95% CI:1.69-12.19), vasopressor use (AOR=10.01, 95% CI: 4.27-22.73), presence of comorbidity(AOR=3.42, 95% CI:1.56-7.51), advanced stage of AKI: stage II (AOR= 2.51, 95% CI:1.15-5.45) and stage III (AOR=2.92, 95%CI: 1.29-6.57), intrinsic type of AKI(AOR=3.56, 95%CI:1.57-8.06) and age above 60 years(AOR=5.50, 95%CI: 2.26-13.41) were associated with poor patient outcome defined by development of complications, need for dialysis or death.
conclusionsThis study revealed that there is a significant level of poor patient outcomes in hospitalized patients with renal failure. Patients receiving partial or no drug dose adjustments were associated with significantly poorer clinical outcomes along with other factors including old age, presence of comorbidities, severity and type of AKI. Therefore, we recommend a holistic approach in the care of renal patients and prompt consideration of adherence to guidelines in drug dosing.
trial registrationWas not applicable because the study was not clinical trial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.